Four is More! Selecting and Optimizing Quadruplet Therapy in NDMM
How I Practice Video ~ Efficacy of Quad Therapies
Activity Post-Survey & Application for Credit

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

* 1. What are your specialty & credentials?

Hematologist

Medical Oncologist

Surgical Oncologist

Radiation Oncologist

Pathologist

Other MD/DO

Trainee/Fellow

Nurse

Pharmacist

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Industry

Other (please specify)

Question Title

* 3. In the IMROZ phase III trial of transplant-ineligible, newly diagnosed multiple myeloma (TIE NDMM), the addition of isatuximab to VRd (Isa VRd), followed by maintenance with Rd ± Isa, resulted in which of the following demonstrated outcomes?

Significantly increased rates of MRD negativity that were not sustained beyond 12 months

Higher discontinuation rates secondary to increased toxicity

A statistically significant improvement in progression-free survival (PFS)

A statistically significant improvement in overall survival (OS)

Question Title

* 4. Which one of the following patients is the most suitable candidate for initiating a quadruplet induction regimen in newly diagnosed multiple myeloma (NDMM)?

A 65 year old woman with ECOG PS 3, significant cardiac and renal impairment, limited social support, and transplant-ineligible (TIE)

A 75 year old man with ECOG PS 0, minimal comorbidities, eligible for autologous SCT and strong social support

An 80 year old woman with ECOG PS 1, diabetes and peripheral neuropathy, and borderline transplant eligibility (TE)

A 72 year old man with ECOG PS 2, hypertension and early CKD, marginal social support, and transplant-ineligible (TIE)

Question Title

* 5. Several phase III trials, including CEPHEUS and GMMG-HD7, have evaluated the impact of adding anti-CD38 antibodies to standard induction regimens in NDMM. Which of the following best describes the observed improvement in MRD-negativity rates following quadruplet induction therapy?

MRD-negativity rates are improved in both transplant-eligible (TE) and transplant-ineligible (TIE) patients, and progression-free survival (PFS) is prolonged

MRD-negativity rates are improved in both TE and TIE patients, but are not sustained over time

MRD-negativity rates are improved in both TE and TIE patients, but PFS is unaffected

MRD-negativity rates improve only in TE patients; no benefit is not observed in TIE patients

EVALUATION FORM

Question Title

* 6. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
Appraise efficacy data from pivotal clinical trials assessing current and emerging quadruplet therapies	Appraise efficacy data from pivotal clinical trials assessing current and emerging quadruplet therapies Strongly agree	Appraise efficacy data from pivotal clinical trials assessing current and emerging quadruplet therapies Agree	Appraise efficacy data from pivotal clinical trials assessing current and emerging quadruplet therapies Disagree	Appraise efficacy data from pivotal clinical trials assessing current and emerging quadruplet therapies Strongly disagree
Define patient-specific factors impacting quadruplet therapy selection for patients with NDMM	Define patient-specific factors impacting quadruplet therapy selection for patients with NDMM Strongly agree	Define patient-specific factors impacting quadruplet therapy selection for patients with NDMM Agree	Define patient-specific factors impacting quadruplet therapy selection for patients with NDMM Disagree	Define patient-specific factors impacting quadruplet therapy selection for patients with NDMM Strongly disagree
Interpret the role of MRD in guiding decision-making for patients with NDMM	Interpret the role of MRD in guiding decision-making for patients with NDMM Strongly agree	Interpret the role of MRD in guiding decision-making for patients with NDMM Agree	Interpret the role of MRD in guiding decision-making for patients with NDMM Disagree	Interpret the role of MRD in guiding decision-making for patients with NDMM Strongly disagree

Question Title

* 7. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective	The faculty for this activity were effective Strongly agree	The faculty for this activity were effective Agree	The faculty for this activity were effective Disagree	The faculty for this activity were effective Strongly disagree
The educational resources provided to me at the educational activity are useful to my practice	The educational resources provided to me at the educational activity are useful to my practice Strongly agree	The educational resources provided to me at the educational activity are useful to my practice Agree	The educational resources provided to me at the educational activity are useful to my practice Disagree	The educational resources provided to me at the educational activity are useful to my practice Strongly disagree

Question Title

* 8. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

* 9. If no, please explain:

Question Title

* 10. Of the patients with multiple myeloma you will see in the next month, about how many will benefit from the information you learned today?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 11. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Expanded use of novel therapies and appropriate uses in NDMM

Application of cutting-edge science in this therapeutic area

Appropriate sequencing of therapeutics

Monitoring and mitigation of TRAEs

Implementation of best practices of my colleagues and leaders

I do not plan on making changes to my practice at this time

Other (explain)

Question Title

* 12. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding treatment options (patient-related)

Patient adherence/resistance to new therapeutics and/or clinical trial enrollment (patient-related barrier)

Limited knowledge regarding new therapeutics for <insert disease state here> (provider-level barrier)

Lack of time resources to consider change (practice-related barrier)

Inadequate support staff for pt education/insurance/billing/administrative issues (practice-level barrier)

Insurance reimbursement or legal issues (systems-related barrier)

Lack of access to novel therapeutics due to regulatory approvals/insurance coverage (systems-related barrier)

Other (please specify)

Question Title

* 13. For purposes of certification, you must complete the following information.
Please note that we will not forward or sell your contact information.

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

* 14. I certify that I have participated in the continuing education activity entitled, "Four is More: Selecting and Optimizing Quadruplet Therapy in Newly Diagnosed Multiple Myeloma | How I Practice" and claim 0.5 AMA PRA Category 1 Credit^TM.

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Four is More! Selecting and Optimizing Quadruplet Therapy in NDMMHow I Practice Video ~ Efficacy of Quad Therapies*Activity Post-Survey & Application for Credit*

Question Title

* 1. What are your specialty & credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. In the IMROZ phase III trial of transplant-ineligible, newly diagnosed multiple myeloma (TIE NDMM), the addition of isatuximab to VRd (Isa VRd), followed by maintenance with Rd ± Isa, resulted in which of the following demonstrated outcomes?

Question Title

* 4. Which one of the following patients is the most suitable candidate for initiating a quadruplet induction regimen in newly diagnosed multiple myeloma (NDMM)?

Question Title

* 5. Several phase III trials, including CEPHEUS and GMMG-HD7, have evaluated the impact of adding anti-CD38 antibodies to standard induction regimens in NDMM. Which of the following best describes the observed improvement in MRD-negativity rates following quadruplet induction therapy?

Question Title

* 6. Upon completion of this activity, I am able to:

Question Title

* 7. Please indicate the extent of your agreement with the following statements:

Question Title

* 8. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 9. If no, please explain:

Question Title

* 10. Of the patients with multiple myeloma you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 11. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 12. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 13. For purposes of certification, you must complete the following information. *Please note that we will not forward or sell your contact information.*

Question Title

* 14. I certify that I have participated in the continuing education activity entitled, "Four is More: Selecting and Optimizing Quadruplet Therapy in Newly Diagnosed Multiple Myeloma | How I Practice" and claim 0.5 AMA PRA Category 1 CreditTM.

Four is More! Selecting and Optimizing Quadruplet Therapy in NDMM
How I Practice Video ~ Efficacy of Quad Therapies
Activity Post-Survey & Application for Credit

* 3. In the IMROZ phase III trial of transplant-ineligible, newly diagnosed multiple myeloma (TIE NDMM), the addition of isatuximab to VRd (Isa VRd), followed by maintenance with Rd ± Isa, resulted in which of the following demonstrated outcomes?

* 13. For purposes of certification, you must complete the following information.
Please note that we will not forward or sell your contact information.

* 14. I certify that I have participated in the continuing education activity entitled, "Four is More: Selecting and Optimizing Quadruplet Therapy in Newly Diagnosed Multiple Myeloma | How I Practice" and claim 0.5 AMA PRA Category 1 Credit^TM.